Endsulin
Gary Mansfield, PhD, serves as Principal at Gene-X BioConsulting, LLC, specializing in preclinical strategies for AAV gene therapies targeting rare diseases since May 2019. Additional roles include Senior Consultant for product development at Endsulin and previous positions as Chief Development Officer at Aspa Therapeutics and BridgeBio, where responsibilities encompassed budget management, scientific team oversight, and collaboration with CROs and partners. With experience at American Gene Technologies as VP of Preclinical Development and Director of Preclinical Operations at Mesoblast, Gary has a proven track record in managing preclinical programs and developing operational strategies. A background in biologics development at WuXi AppTec and leadership roles at VIRxSYS Corporation and Intronn Inc. contribute to Gary's extensive experience in advancing gene therapy projects from discovery to clinical phases. Educational qualifications include a Bachelor of Science in Plant Biology and Marine Biology from UCNW Bangor and a PhD in Cell/Cellular Biology and Anatomical Sciences from the University of Nottingham.
This person is not in the org chart
This person is not in any teams
Endsulin
Endsulin is a pre-clinical stage gene therapy company whose mission is to end insulin dependence for good and free people from being defined by diabetes. Our approach employs a widely studied and proven viral vector to deliver our patented genetic factor to the liver and restore the body’s own ability to produce and regulate insulin. With a single administration, Endsulin’s revolutionary genetic therapy for T1DM delivers a patented genetic factor that will “switch on” new insulin-producing cells to confer years – and perhaps a lifetime – of freedom from injecting artificial insulin, realizing the goal that has eluded researchers since the discovery of insulin. Founded by an award-winning transplant surgeon and world leader in diabetes care and supported by a team of experts in gene therapy, endocrinology, diabetes science, and pharmaceutical development, Endsulin has the scientific, medical, and commercial expertise to develop its innovative therapy quickly, filling an enormous unmet need and bringing us one step closer to ending insulin dependence for good — and for the good of everyone with T1DM.